Presbia PLC (NASDAQ:LENS) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Brokers have set a 1 year consensus price objective of $8.50 for the company and are predicting that the company will post ($0.27) earnings per share for the current quarter, according to Zacks. Zacks has also given Presbia an industry rank of 161 out of 265 based on the ratings given to its competitors.
Several brokerages have commented on LENS. Zacks Investment Research upgraded shares of Presbia from a “sell” rating to a “hold” rating in a report on Tuesday, December 5th. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Presbia in a report on Wednesday, December 20th.
Shares of Presbia (NASDAQ:LENS) opened at $3.29 on Monday. The company has a quick ratio of 2.94, a current ratio of 3.02 and a debt-to-equity ratio of 0.07. Presbia has a 1-year low of $1.86 and a 1-year high of $7.14. The company has a market cap of $56.33, a PE ratio of -2.84 and a beta of -0.13.
TRADEMARK VIOLATION NOTICE: “Presbia PLC (LENS) Receives Average Rating of “Strong Buy” from Brokerages” was published by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/02/05/presbia-plc-lens-receives-average-rating-of-strong-buy-from-brokerages.html.
Presbia Company Profile
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Presbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia and related companies with MarketBeat.com's FREE daily email newsletter.